+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
ID06278454

Phase I Study to Assess Safety and Effectiveness of NRT6008 Injection Combined with Chemotherapy for Unresectable Locally Advanced and Advanced Pancreatic Cancer with Lymph Node Metastases

Led by Chengdu New Radiomedicine Technology Co. LTD. · Updated on 2026-06-10

58

Participants Needed

6

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase I clinical trial to evaluate the safety and efficacy of NRT6008 injection in patients with unresectable locally advanced pancreatic cancer LAPC or advanced pancreatic cancer with lymph node metastases. This study is open-label and single-arm, aiming primarily to assess safety and tolerance, with secondary goals including preliminary efficacy, distribution of the injection in the body, changes in tumor biomarkers, and improvements in cancer pain. Safety and efficacy data will be monitored by independent committees throughout the trial. Participants will receive NRT6008 injection implanted into the pancreatic tumor through an endoscopic ultrasound-guided fine-needle injection. This will be combined with chemotherapy, with the regimen chosen by investigators based on participant condition options include gemcitabine plus nab-paclitaxel GN, FOLFIRINOX, or modified FOLFIRINOX mFOLFIRINOX. Chemotherapy cycles vary between 2 to 4 weeks, and the NRT6008 dose is tailored according to tumor volume and absorbed dose. The study includes a dose escalation phase and a dose expansion phase to determine the maximum tolerated dose or recommended phase 1 dose. Participants will be involved in assessments for adverse events and toxicity up to 52 weeks after administration. Efficacy measures such as objective response rate, duration of response, progression-free survival, overall survival, and surgical resection rates will be evaluated during this period. The study also monitors tumor biomarker changes and cancer pain status. Participant involvement includes multiple visits for treatment administration, safety monitoring, and efficacy evaluations over the course of the study.

CONDITIONS

Brief Title

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases

Research Team

Z

Zhaoshen Li, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here